- Atezolizumab added to neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) yielded no improvements in pathologic complete response (pCR).
- These results are preliminary findings from the NeoTRIPaPDL1 trial.
Why this matters
- This trial is part of the quest for interventions beyond chemotherapy for this aggressive disease with a high relapse probability.
- The authors caution that longer term results may change conclusions and that the primary endpoint of the study is event-free survival, not pCR.
- Clinical overall response rates were 76.1% (95% CI, 68.1%-82.9%) with atezolizumab vs 68.3% (60.0%-75.9%) without.
- In the intention-to-treat analysis, pCR rates were:
- 43.5% (95% CI, 35.1%-52.2%) with atezolizumab and 40.8% (32.7%-49.4%) without (OR, 1.11; P=.66).
- In the safety data, abnormal liver enzymes stood out in the atezolizumab group.
- Multicenter open-label trial with 280 participants with TNBC randomly allocated to neoadjuvant treatment with or without atezolizumab.
- Primary outcome: event-free survival at 5 years.
- Secondary outcome: pCR.
- Funding: Hoffmann-La Roche, Ltd; Celgene International Sarl.
- Post-surgery effects of therapy not yet included.
- Results presented at a conference without peer review.